BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

MediGene AG (DX:MDG) Successfully Completes Pivotal Clinical Phase III Trials Of Polyphenon® E Ointment For The Treatment Of Genital Warts


10/19/2005 5:12:25 PM

The German-American biotech company MediGene AG (Frankfurt, Prime Standard: MDG) announces the successful closure of the Americas phase III trial of Polyphenon® E Ointment* for the treatment of anogenital and perianal warts, thus fulfilling the clinical requirements for filing an marketing application (NDA). The outcome of this statistically significant trial with more than 500 patients demonstrates significant efficacy of the ointment compared to placebo as well as good tolerability. The data obtained surpass the positive results MediGene had received in the comparable European phase III trial on more than 500 patients, completed in March 2004. The company plans to submit an NDA in the US, in mid 2005, followed by submission in Europe.


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES